Docbot lands a healthy $4M in series A financing

A check up by Khosla Ventures determined that Docbot Inc. was healthy enough for the prominent biotech investor to take the lead in a $4 million series A round. The new funds bring the artificial intelligence company to a total of $8.5 million in capital raised to date. Other participants included Bold Capital Partners, Collaborative Fund and Boutique Venture Partners. Docbot's platform, Ultivision AI, uses artificial intelligence to enhance detection of gastrointestinal (GI) disease. The Irvine, Calif.-based company is targeting identification and classification of polyps, Barrett's esophagus, and ulcerative colitis to start.